• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

白细胞介素-2:癌症治疗中给药途径及当前递送系统的评估

Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy.

作者信息

Shaker Mohamed A, Younes Husam M

机构信息

School of Pharmacy, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.

出版信息

J Pharm Sci. 2009 Jul;98(7):2268-98. doi: 10.1002/jps.21596.

DOI:10.1002/jps.21596
PMID:19009549
Abstract

Despite the fact that different administration routes and delivery systems have been used for interleukin-2 (IL-2) delivery, little has been reported regarding the most efficient strategies used to deliver IL-2 in a nontoxic, efficient, stable and safe manner. Systemic IL-2 administration has always been associated with rapid clearance and severe toxicity as a result of its narrow therapeutic index. Loco-regional IL-2 delivery, however, is used to localize IL-2 actions and activities into the vicinity of tumors and can result in an improved therapeutic outcome with much less side effects or toxicity. The purpose of this review is to report on the different properties and aspects of IL-2, including its mechanism of action, physicochemical properties, and structure which have an impact on the activity, stability and formulation of IL-2 dosage forms and delivery systems. In addition, advantages and limitations of the currently available techniques and strategies to deliver IL-2 will also be covered.

摘要

尽管已经采用了不同的给药途径和递送系统来递送白细胞介素-2(IL-2),但关于以无毒、高效、稳定和安全的方式递送IL-2的最有效策略的报道却很少。由于其治疗指数狭窄,全身性IL-2给药一直与快速清除和严重毒性相关。然而,局部区域IL-2递送用于将IL-2的作用和活性定位在肿瘤附近,并且可以在副作用或毒性小得多的情况下产生改善的治疗效果。本综述的目的是报告IL-2的不同特性和方面,包括其作用机制、物理化学性质以及对IL-2剂型和递送系统的活性、稳定性和制剂有影响的结构。此外,还将涵盖目前可用的IL-2递送技术和策略的优点和局限性。

相似文献

1
Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy.白细胞介素-2:癌症治疗中给药途径及当前递送系统的评估
J Pharm Sci. 2009 Jul;98(7):2268-98. doi: 10.1002/jps.21596.
2
Interferon-gamma therapy: evaluation of routes of administration and delivery systems.干扰素-γ疗法:给药途径与递送系统的评估
J Pharm Sci. 2002 Jan;91(1):2-17. doi: 10.1002/jps.10007.
3
Effects of route and formulation on clinical pharmacokinetics of interleukin-2.给药途径和剂型对白介素-2临床药代动力学的影响。
Clin Pharmacokinet. 1994 Jul;27(1):19-31. doi: 10.2165/00003088-199427010-00003.
4
ReGel polymer-based delivery of interleukin-2 as a cancer treatment.
J Immunother. 2006 Sep-Oct;29(5):524-35. doi: 10.1097/01.cji.0000211306.05869.25.
5
New clinical trials with interleukin-2: rationale for regional administration.白细胞介素-2的新临床试验:区域给药的理论依据。
Nat Immun Cell Growth Regul. 1989;8(3):153-64.
6
Nanoparticles for delivery of chemotherapeutic agents to tumors.用于将化疗药物递送至肿瘤的纳米颗粒。
Curr Opin Investig Drugs. 2007 Jun;8(6):477-84.
7
Interleukin 1 trials in cancer patients: a review of the toxicity, antitumor and hematopoietic effects.癌症患者的白细胞介素-1试验:毒性、抗肿瘤及造血作用综述
Stem Cells. 1996 Mar;14(2):164-76. doi: 10.1002/stem.140164.
8
Delivery of anticancer drugs.抗癌药物的递送
Methods Find Exp Clin Pharmacol. 1989 Jul-Aug;11(7-8):439-529.
9
[Certain possible complications and side effects after the introduction of interleukin-2 in the scheme of treatment of surgical patients].[在手术患者治疗方案中引入白细胞介素-2后某些可能的并发症和副作用]
Vestn Khir Im I I Grek. 2009;168(5):86-90.
10
Nanoscale delivery systems for multiple drug combinations in cancer.用于癌症多药物组合的纳米递药系统。
Future Oncol. 2011 Nov;7(11):1347-57. doi: 10.2217/fon.11.109.

引用本文的文献

1
The present and future of immunocytokines for cancer treatment.免疫细胞因子在癌症治疗中的现状和未来。
Cell Mol Life Sci. 2022 Sep 6;79(10):509. doi: 10.1007/s00018-022-04514-9.
2
Engineering Strategies for Immunomodulatory Cytokine Therapies - Challenges and Clinical Progress.免疫调节细胞因子疗法的工程策略——挑战与临床进展
Adv Ther (Weinh). 2021 Aug;4(8). doi: 10.1002/adtp.202100035. Epub 2021 Apr 2.
3
Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies.
在分子靶向和免疫治疗时代,高级别脑胶质瘤在早期药物开发过程中的治疗反应评估。
Cancer J. 2021;27(5):395-403. doi: 10.1097/PPO.0000000000000543.
4
Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors.下一代成像技术在实体瘤中定义免疫拓扑结构。
Front Immunol. 2021 Jan 27;11:604967. doi: 10.3389/fimmu.2020.604967. eCollection 2020.
5
Imaging of T-cells and their responses during anti-cancer immunotherapy.在癌症免疫治疗期间 T 细胞及其反应的成像。
Theranostics. 2019 Oct 16;9(25):7924-7947. doi: 10.7150/thno.37924.
6
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.免疫治疗联合靶向治疗:转移性黑色素瘤的理论与实践。
Front Immunol. 2019 May 7;10:990. doi: 10.3389/fimmu.2019.00990. eCollection 2019.
7
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma.皮肤黑色素瘤联合免疫治疗试验中的免疫调节单克隆抗体
Front Immunol. 2017 Aug 25;8:1024. doi: 10.3389/fimmu.2017.01024. eCollection 2017.
8
Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.白细胞介素-2:增强免疫治疗疗效的新旧方法
Adv Exp Med Biol. 2017;995:33-51. doi: 10.1007/978-3-319-53156-4_2.
9
Functional Modulation of Regulatory T Cells by IL-2.白细胞介素-2对调节性T细胞的功能调节
PLoS One. 2015 Nov 3;10(11):e0141864. doi: 10.1371/journal.pone.0141864. eCollection 2015.
10
Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.免疫疗法与癌基因靶向疗法相结合:黑色素瘤治疗的新途径。
Front Immunol. 2015 Feb 9;6:46. doi: 10.3389/fimmu.2015.00046. eCollection 2015.